The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Fedorova Ia.B.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Current approaches to the treatment of fronto-temporal dementia

Authors:

Fedorova Ia.B.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9‑2): 18‑24

DOI: 10.17116/jnevro201911909218

Read: 24694 times

Contact the author
Table of contents

CURRENT APPROACHES TO THE TREATMENT OF FRONTO-TEMPORAL DEMENTIA
CURRENT APPROACHES TO THE TREATMENT OF FRONTO-TEMPORAL DEMENTIA

To cite this article:

Fedorova IaB. Current approaches to the treatment of fronto-temporal dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9‑2):18‑24. (In Russ.)
https://doi.org/10.17116/jnevro201911909218

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Frontotemporal dementias (FTD) are one of the prevalent forms of early neurodegenerative diseases. FTD are characterized by heterogeneous clinical manifestations and syndromes. The current methods of FTD treatment and the clinical trials of new methods of FTD treatment are considered in the article. Biomarkers and their relationships with the results of recently completed clinical trials, as well as future therapeutic perspectives, are reviewed.

Keywords:

frontotemporal dementia
behavioral variant of frontotemporal dementia
primary progressive aphasia
semantic dementia
therapeutic techniques of frontotemporal dementia

Authors:

Fedorova Ia.B.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Close metadata

References:

  1. Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;24:1672-1682. https://doi.org/10.1016/S0140-6736(15)00461-4
  2. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology. 2002;58(11):1615-1662.
  3. Rohrer JD, Guerreiro R, Vandrovcova J, Uphill J, Reiman D, Beck J, Isaacs AM, Authier A, Ferrari R, Fox NC, Mackenzie IR, Warren JD, de Silva R, Holton J, Revesz T, Hardy J, Mead S, Rossor MN. The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009;73:1451-1456. https://doi.org/10.1212/WNL.0b013e3181bf997a
  4. Le Ber I. Genetics of frontotemporal lobar degeneration: an up-date and diagnosis algorithm. Rev Neurol. 2013;169:811-819. https://doi.org/10.1016/j.neurol.2013.07.014
  5. Goldman JS, Rademakers R, Huey ED, Boxer AL, Mayeux R, Miller BL, Boeve BF. An algorithm for genetic testing of frontotemporal lobar degeneration. Neurology. 2011;76:475-483. https://doi.org/10.1212/WNL.0b013e31820a0d13
  6. Riedl L, Mackenzie IR, Förstl H, Kurz A, Diehl-Schmid J.Frontotemporal lobar degeneration: current perspectives. Neuropsychiatr Dis Treat. 2014;10:297-310. https://doi.org/10.2147/NDT.S38706
  7. Boxer AL, Boeve BF. Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer Dis Assoc Disord. 2007;21(4):79-87.
  8. Nardell M, Tampi RR. Pharmacological treatments for frontotemporal dementias: a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2014;29(2):123-132. https://doi.org/10.1177/1533317513507375
  9. López-Pousa S, Calvó-Perxas L, Lejarreta S, Cullell M, Meléndez R, Hernández E, Bisbe J, Perkal H, Manzano A, Roig AM, Turró-Garriga O, Vilalta-Franch J, Garre-Olmo J; Registry of Dementias of Girona Study Group (ReDeGi Study Group). Use of antidementia drugs in frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 2012;27(4):260-266. https://doi.org/10.1177/1533317512447887
  10. Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66(1):17-22. https://doi.org/10.1212/01.wnl.0000191304.55196.4d
  11. Swartz JR, Miller BL, Lesser IM, Darby AL.Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997;58(5):212-216.
  12. Mendez MF. Frontotemporal dementia: therapeutic interventions. Front Neurol Neurosci. 2009;24:168-178. https://doi.org/10.1159/000197896
  13. Fellgiebel A, Müller MJ, Hiemke C, Bartenstein P, Schreckenberger M.Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry. 2007;8(2):123-126. https://doi.org/10.1080/15622970601016538
  14. Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer’s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18(4):205-214. https://doi.org/10.1177/153331750301800410
  15. Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15(1):84-87. https://doi.org/10.1097/01.JGP.0000231744.69631.33
  16. Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in Frontotemporal dementia: an open-label study. Drugs Aging. 2004;21:931-937. https://doi.org/10.2165/00002512-200421140-00003
  17. Kertesz A, Morlog D, Light M, Blair M, Davidson W, Jesso S, Brashear R. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25(2):178-185. https://doi.org/10.1159/000113034
  18. O’Brien JT, Burns A; BAP Dementia Consensus Group. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(8):997-1019. https://doi.org/10.1177/0269881110387547
  19. Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. 2007;21(2):164-166. https://doi.org/10.1097/WAD.0b013e318047df5d
  20. Boxer AL, Knopman DS, Kaufer DI, Grossman M, Onyike C, Graf-Radford N, Mendez M, Kerwin D, Lerner A, Wu CK, Koestler M, Shapira J, Sullivan K, Klepac K, Lipowski K, Ullah J, Fields S, Kramer JH, Merrilees J, Neuhaus J, Mesulam MM, Miller BL. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12(2):149-156. https://doi.org/10.1016/S1474-4422(12)70320-4
  21. Chow TW, Fam D, Graff-Guerrero A, Verhoeff NP, Tang-Wai DF, Masellis M, Black SE, Wilson AA, Houle S, Pollock BG. Fluorodeoxyglucose positron emission tomography in semantic dementia after 6 months of memantine: an open-label pilot study. Int J Geriatr Psychiatry. 2013;28(3):319-325. https://doi.org/10.1002/gps.3832
  22. Kishi T, Matsunaga S, Iwata N. Memantine for the treatment of frontotemporal dementia: a meta-analysis. Neuropsychiatr Dis Treat. 2015;11:2883-2885. https://doi.org/10.2147/NDT.S94430
  23. Ikeda M, Shigenobu K, Fukuhara R, Hokoishi K, Maki N, Nebu A, Komori K, Tanabe H. Efficacy of fluvoxamine as a treatment for behavioral symptoms in FTLD patients. Dement Geriatr Cogn Disord. 2004;17:117-121. https://doi.org/10.1159/000076343
  24. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314.
  25. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State. A practical method of grading the cognitive state of patients for the clinician. Journal of Psychiatry Research. 1975;12:189-198.
  26. Lebert F, Stekke W, Hasenbroekx C, Pasquier F.Frontotemporal dementia: a randomized, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17:335-359. https://doi.org/10.1159/000077171
  27. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: Paroxetine as a possible treatment of behavioral symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49:13-19. https://doi.org/10.1159/000067021
  28. Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology. 2004;172:400-408. https://doi.org/10.1007/s00213-003-1686-5
  29. Fellgiebel A, Müller MJ, Hiemke C, Bartenstein P, Schreckenberger M. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry. 2007;8(2):123-126. https://doi.org/10.1080/15622970601016538
  30. Chow TW, Mendez MF. Goals in symptomatic pharmacologic management of Frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 2002;17:256-272. https://doi.org/10.1177/153331750201700504
  31. Pijnenburg YA, Sampson EL, Harvey RJ, Fox NC, Rossor MN. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatry. 2003;18(1):67-72. https://doi.org/10.1002/gps.774
  32. Cruz M, Marincho V, Fontenelle LF,Engelhardt E, Laks J. Topiramate may modulate alcohol abuse but not other compulsive behaviors in frontotemporal dementia: case report. Cogn Behav Neurol. 2008;21:104-106.
  33. Jesso S, Morlog D, Ross S, Pell MD, Pasternak SH, Mitchell DG, Kertesz A, Finger EC.The effects of oxytocin on social cognition and behaviour in frontotemporal dementia. Brain. 2011;134(9):2493-2501. https://doi.org/10.1093/brain/awr171
  34. Finger EC, MacKinley J, Blair M, Oliver LD, Jesso S,Tartaglia M, Borrie M, Wells J, Dziobek I, Pasternak S, Mitchell D, Rankin K, Kertesz A, Boxer A. Oxytocin for frontotemporal dementia: a randomized dose finding study of safety and tolerability. Neurology. 2015;13:174-181. https://doi.org/10.1212/WNL.0000000000001133
  35. Dolder CR, Davis LN, McKinsey J. Use of psychostimulants in patients with dementia. Ann Pharmacother. 2010;44(10):1624-1632. https://doi.org/10.1345/aph.1P341
  36. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42-5231. https://doi.org/10.1016/j.neuron.2009.03.024
  37. Sanders DW, Kaufman SK, De Vos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, Serpell LC, Miller TM, Grinberg LT, Seeley WW, Diamond MI. Distinct tau prion strains propagate in cells and mice and defi ne diff erent tauopathies. Neuron. 2014;82:1271-1288. https://doi.org/10.1016/j.neuron.2014.04.047
  38. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80:402-414. https://doi.org/10.1016/j.neuron.2013.07.046
  39. Wischik CM, Harrington CR, Storey JM. Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem Pharmacol. 2014;88:529-539. https://doi.org/10.1016/j.bcp.2013.12.008
  40. Cenik B, Sephton CF, Dewey CM, Xian X, Wei S, Yu K, Niu W, Coppola G, Coughlin SE, Lee SE, Dries DR, Almeida S, Geschwind DH, Gao FB, Miller BL, Farese RV Jr, Posner BA, Yu G, Herz J. Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J Biol Chem. 2011;286:16101-16108. https://doi.org/10.1074/jbc.M110.193433
  41. Capell A, Liebscher S, Fellerer K, Brouwers N, Willem M, Lammich S, Gijselinck I, Bittner T, Carlson AM, Sasse F, Kunze B, Steinmetz H, Jansen R, Dormann D, Sleegers K, Cruts M, Herms J, Van Broeckhoven C, Haass C. Rescue of progranulin defi ciency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J Neuro. 2011;31:1885-1894. https://doi.org/10.1523/JNEUROSCI.5757-10.2011
  42. Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386:1672-1682. https://doi.org/10.1016/S0140-6736(15)00461-4
  43. Kolykhalov IV. Frontotemporal dementia in psychiatric practice: diagnostic and therapeutic aspects. Obozrenie Psikhiatrii i Meditsinskoj Psikhologii im. V.M. Bekhtereva. 2018;2:109-115. (In Russ.) https://doi.org/10.31363/2313-7053-2018-2-109-115
  44. Merrilees J. A model for management of behavioral symptoms in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2007;21:64-69. https://doi.org/10.1097/WAD.0b013e31815bf774
  45. Cheng ST, Chow PK, Song YQ, Yu EC, Chan AC, Lee TM, Lam JH. Mental and physical activities delay cognitive decline in older persons with dementia. AM J Geriatr Psychiatry. 2014;22:63-67.
  46. Ikeda M, Tanabe H, Horino T, Komori K, Hirao K, Yamada N, Hashimoto M, Kazui H, Mori T. Care for patients with Pick’s disease — by using their preserved procedural memory. Seishin Shinkeigaku Zasshi. 1995;97:179-192.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.